Drug Profile
Research programme: antibacterial peptides - Tamarkin Pharmaceutical Innovation
Latest Information Update: 03 May 2007
Price :
$50
*
At a glance
- Originator Tamarkin Pharmaceutical Innovation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 23 Jan 2001 This programme is available for licensing
- 23 Jan 2001 Preclinical development for Bacterial infections in Israel (Unknown route)